- 3 Oct 2019 Kymab Announces Presentation on KY1049 at the European Congress on Thrombosis and Haemostasis
- 1 Jun 2019 Kymab Poster on Adaptive Phase 1/2 Clinical Trial for KY1044 anti-ICOS Program at 2019 ASCO Meeting
- 18 Apr 2018 Kymab presents data on two of its immuno-oncology antibodies, providing further evidence of the strength of its franchise
- 12 Jan 2018 Kymab ‘top European biotech to watch’ in 2018
- 4 Dec 2017 Anti-PD-L1 antibody KY1003 shows anti-tumour efficacy
- 8 Nov 2017 KY1044 strongly inhibits tumour growth in models
- 21 Sep 2017 KY1005 impressive in acute GVHD model
- 31 Jul 2017 Kymab's KY1005 antibody in clinical trial
- 23 Jan 2017 Arndt Schottelius appointed Executive VP R&D
- 9 Jan 2017 Kymab expands Infectious Disease Programmes
We use cookies on our website. Carry on browsing if you’re happy with this or find out more
Featured article: Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies
LifeArc will make a US$30 million equity investment in Kymab LifeArc to gain access to IntelliSelect platforms to enhance ...
Read article
Featured article: Kymab Announces Presentations at the 24th EHA Annual Congress
Two Company-sponsored oral and poster abstracts to be presented on KY1049 and IntelliSelect® Bispecifics platform
Read article